Poseida Therapeutics, Inc.
Poseida Therapeutics, Inc. (PSTX) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
pstx · stock forecast · 6 analysts (3M) · FMP · updated Apr 25, 2025
Analyst Rating & Consensus
Based on 6 Wall Street analysts in the past 3 months
Buy
6 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$15.00
Consensus
$12.50
+31.6% upside
Low
$10.00
Median: $12.5 · Last Close: $9.50
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$12.50
31.6% upside
High Target
$15
57.9%
Low Target
$10
5.3%
Current Price
$9.50
as of today
Based on analyst price targets, the PSTX stock price prediction for the next 12 months ranges from $10 to $15. The consensus PSTX price forecast of $12.50 implies 31.6% upside from the current price of $9.50.
Short-Term Price Prediction
RangingAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $9.51 | ↑ 0.07% |
1-day model range: $9.5–$9.52. Peak: $9.52 (+0.07%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · PSTX · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2024-11-26 | William Blair | Downgrade ↓ | Outperform→Market Perform |
| 2024-11-26 | HC Wainwright & Co. | Downgrade ↓ | Buy→Neutral |
| 2024-11-26 | BTIG | Downgrade ↓ | Buy→Neutral |
| 2024-11-15 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-11-08 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-10-30 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-10-17 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-08-06 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-07-25 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-05-22 | HC Wainwright & Co. | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Poseida Therapeutics, Inc. (PSTX) stock. Of the recent 35 rating actions, 0 were upgrades and 3 were downgrades. 6 analysts currently cover PSTX.
Analyst Recommendation Trends
PSTX analyst recommendation trends show increasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 2 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$147M
↑ 234.4% YoY
Revenue Next Year
$43M
↓ 70.5% YoY
EPS This Year
$-0.73
EPS Next Year
$-1.82
↑ 150.0% YoY
EPS ForecastReported vs Estimated
Analysts forecast PSTX EPS of $-0.73 for the current fiscal year, based on estimates from 2 analysts. The PSTX revenue forecast is $147M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The PSTX stock forecast is supported by two independent data sources: analyst consensus ratings from 6 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus PSTX price target is $12.50 (+31.6% upside), with an analyst consensus of Buy.
The PSTX short-term stock prediction for tomorrow is $9.51 (+0.07%).
Poseida Therapeutics, Inc. trades on NASDAQ under the ticker PSTX. The PSTX stock outlook for 2027 is broadly positive, supported by a Buy consensus among 50% of covering analysts.
Frequently asked questions
PSTX forecast · 8 questionsAccording to 6 Wall Street analysts, the average 12-month PSTX price target is $12.50, with a high forecast of $15.00 and a low of $10.00. The median price target is shown in the chart above when available. This implies +31.6% potential upside from the current price of $9.50.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.